6 AI companies are helping pharmaceutical companies streamline clinical trials

For the past year, pharmaceutical companies have been talking about the potential for drugs discovered or designed by artificial intelligence. They tout AI as having the potential to accelerate the pace of new drugs approved to treat everything from rare diseases to cancer to antibiotic-resistant infections.

It will take years in the research pipeline to confirm whether these claims are true. Meanwhile, other companies are deploying machine learning and artificial intelligence in the design and conduct of clinical trials for existing drug candidates, hoping for faster returns.

The ultimate manifestation of artificial intelligence in clinical trials is total simulation. There are no human participants, and we only predict clinical and safety outcomes based on vast databases of past clinical trials, real-world patient records, pharmacokinetic data, and more. Not surprisingly, “a lot of the applications we’re seeing are still about optimization and not necessarily the wild and cool stuff that people are expecting,” says Morgan, executive director of the Clinical Trials Transformation Initiative.・Hanger says.